Abstract
Current ulcerative colitis (UC) treatments have variable efficacy and may take several weeks to assess improvement. Emerging data suggest the intestinal microbiota may serve as a biomarker and mechanistically may influence immune system activity through epigenetic regulation of host gene expression. The aim of this pilot project was to examine whether the colonic mucosal microbiota and mucosal DNA methylation patterns are associated with a response to treatment in UC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
